ライフサイエンスコーパス: setting where

1 We conclude that in Los Angeles, a setting where there is no ongoing outbreak of drug-resis

2 ces compared with expectant management, in a setting where both managements are commonly practised, a

3 eding in infancy and adult intelligence in a setting where breastfeeding was not linked with socioeco

4 In a setting where daily complementary food supplementation i

5 cy of three preventive-therapy regimens in a setting where exposure to tuberculosis is common.

6 In a setting where HIV care is well organized and antiretrovi

7 approach will have the greatest effect in a setting where implementation of optical coherence tomogr

8 s for inferring functional connectivity in a setting where input to the neuron is controlled.

9 activation by recombinant viral vectors in a setting where preformed Ab to the virus is present and a

10 al variables would not predict survival in a setting where surgical techniques were standardized and

11 hese are important findings, especially in a setting where the concrete BSF has seen high rates of co

12 otional distress than orphans who lived in a setting where the director made decisions, daily routine

13 Orphans who lived in a setting where the entire staff participated in decisions

14 the possibility that it may be helpful in a setting where the global delivery of therapeutic protein

15 of well-established autochthonous tumor in a setting where the host immune system has been conditione

16 d (LOCF), and multiple imputation (MI), in a setting where time-dependent covariates also act as medi

17 tastases; the effect is most pronounced in a setting where tyrosinase-related protein-2 peptide-pulse

18 y of recall and by assessing covariates in a setting where women were examined more than once.

19 illness, the intensive care unit (ICU) is a setting where death is common.

20 y fibroblasts expressing the E1A oncogene, a setting where apoptosis is dependent on endogenous p53.

21 The intensive care unit remains a setting where death is common, and a large proportion of

22 proximity of nick and mismatch represents a setting where repair has not been well characterized, bu

23 ulated during oncogene-induced senescence, a setting where it acts in response to p53 as a direct tra

24 in metastatic RCC as second-line therapy, a setting where no effective systemic therapy is presently

25 significant economic impact in the adjuvant setting where the drug is arbitrarily given for 1 year.

26 ) should be used exclusively in the adjuvant setting, where circulating tumor cells and micrometastas

27 roponin testing, including in the ambulatory setting, where assessment for low-level chronic myocardi

28 odulate myeloid cell functions in anatomical settings where PILRalpha ligands are expressed.

29 were included if they were performed in any setting where suicide completions, suicide attempts, or

30 vances have helped delineate the appropriate settings where inhibiting or promoting autophagy may con

31 occur under mid-ocean ridges or in back-arc settings, where percolating melts enhance the mobility o

32 al cost or duration considerably, as well as settings where potential savings are negligible.

33 This is quite disparate to the H-2(b) setting, where only two epitopes have been identified.

34 al regulatory mechanisms in other biological settings where analogous genomic data are available.

35 l new tool for matrix analysis in biological settings, where the relationship of observed quantities

36 This may be of importance in high-burden settings where > or =1 genetic group of M. tuberculosis

37 ticularly those practicing in the acute care setting where rapid pathogen detection and identificatio

38 ticularly those practicing in the acute-care setting, where rapid pathogen identification may assist

39 In the South African HIV care setting-where TB mortality rates are higher and Ultra's

40 ia testing in public and private health care settings where there are challenges to blood-based malar

41 ion of bloodborne viruses in all health-care settings where skin-piercing procedures are used.

42 ent by uninfected individuals in health-care settings where they may be at increased risk of infectio

43 based detection assays towards point-of-care settings where they are needed most.

44 with isolated fast breathing in primary care settings where hospital referral is often unfeasible.

45 ese results may not be generalizable to care settings where on-site physician HIV experts are not acc

46 ever, its performance in routine health care settings, where adherence to drug treatment is unsupervi

47 ting that the interaction occurs in cellular settings where ABCA1 activity is critical for HDL genesi

48 ncertainty quantification in the challenging setting where the reaction graph is unknown.

49 lopment interventions offered through clinic settings, where access to high-risk adolescents is plent

50 ests for Legionnaires' disease in a clinical setting where Legionella pneumophila PCR had been introd

51 es or provide decision support in a clinical setting where the choice and timing of therapies are cri

52 the mean number of visits, and the clinical setting where care was provided.

53 ession results, particularly in the clinical setting where fold-change differences are typically smal

54 This is critically important in the clinical setting where targeted resequencing is frequently being

55 In a clinical setting, where a change in cTnT was not mandatory for th

56 with the test's accuracy, even in a clinical setting, where operator training is mandated.

57 l differences and be applied in the clinical setting, where patients must be assessed as individuals.

58 to translate these findings to the clinical setting, where reducing patient anxiety is a therapeutic

59 s will have utility in research and clinical settings where panels of mutations or large numbers of s

60 stic tool that can be developed for clinical settings where ease of handling and minimal sample prepa

61 emains challenging, particularly in clinical settings where accuracy and turnaround times are critica

62 t, and this approach may be used in clinical settings where autologous HSC transplant is being perfor

63 ble effects of certain additives in clinical settings where enhanced immune responsiveness can transl

64 In clinical settings where FMT is not available or applicable, the p

65 ings bear potential implications in clinical settings where proteasome peptidase activities are thera

66 hod for measuring oxidant stress in clinical settings where reactive oxygen species are putatively in

67 The device fulfills a need in clinical settings where small amounts of sperm need to be sorted.

68 ach may be most readily realized in clinical settings where the intrinsic risks are low (e.g., stable

69 its utility has been questioned in clinical settings where the prevalence of OM is low.

70 w approach to prevent thrombosis in clinical settings where the risk of clotting is high.

71 c system as well as in some limited clinical settings where real-time visible fluorescence could faci

72 ensors, has proven helpful in other clinical settings where low mean arterial pressure and need for a

73 rategies for detecting dementia in community settings where biomarkers may not be readily available,

74 reak investigations in hospital or community settings where robust clones are endemic.

75 observation that has parallels in corporate settings where middle managers must interact most to ens

76 ly challenging for use in developing country settings, where vitamin A deficiency remains a major pub

77 One critical setting where these limitations are evident is the detec

78 logic management of SS, both in the curative setting, where the standard approach is wide surgical ex

79 toxicity profiles in several common disease settings where conventional treatments have previously p

80 monitor malaria transmission in elimination settings where existing metrics such as parasite prevale

81 s known about the role of climate in endemic settings where clinical immunity develops early in life.

82 y acquired immunity are warranted in endemic settings where transmission has been reduced but persist

83 Using an experimental setting where infected fibroblasts were cocultured with

84 In contrast to the experimental setting, where one of the two branches is often occluded

85 ed and traditionally studied in experimental settings where repeated sequences are present or are bei

86 ression experiments or in noisy experimental settings where a small sub-population of cells contribut

87 hantavirus pulmonary syndrome (HPS) in field settings where advanced instrumentation is not available

88 This suggests that in field settings where mutual shading between plants may occur,

89 ngs with extensive use of lamivudine and for settings where generic lamivudine will be available.

90 tation of a bivariate linear mixed model for settings where hundreds of traits have been measured on

91 second design uses a hierarchical model for settings where, a priori, the experimental treatment eff

92 risks framework, which refers to the general setting where scientific interest lies with some nonterm

93 and tend to accumulate in population-genetic settings where random genetic drift is a relatively stro

94 y means of survival for war orphans, a group setting where the staff shares in the responsibilities o

95 % in the city studied, 67% in the healthcare setting where they had completed a course placement.

96 ield a smaller tidal volume than typical HFO settings where frequency is limited to 6 Hz or less and

97 es but are impractical for use in a hospital setting, where Clostridium difficile spores present a ch

98 articularly relevant concern in the hospital setting, where antibiotic use and antibiotic-resistant p

99 ) therapy while highly effective in the HSCT setting where immunosuppression can be withdrawn have be

100 In hyperendemic settings where mixed infections are common, the Xpert re

101 e FDA Guidelines applied under the idealized setting where the dentists are periodically recalibrated

102 ad contributors, and operating room identify settings where fire risk is enhanced by proximity of tri

103 We illustrate settings where incorporating genetic information could r

104 In other immune settings where initially a limited repertoire of antigen

105 In settings where information about pelvic-floor exercise i

106 In settings where MRSA is prevalent, clindamycin and TMP-SM

107 In settings where so-called standard therapy is not feasibl

108 ctious diseases has largely been achieved in settings where natural immunity to the pathogen results

109 most appropriate technologies are adopted in settings where they will have a sustainable impact.

110 est that enhancement is most advantageous in settings where multiple serotypes circulate and where a

111 ions requiring fast turnaround times, and in settings where a centralized laboratory approach faces l

112 irable, such as infection and cancer, and in settings where tolerance-driving DCs are preferred, such

113 HIVDR mutations affecting first-line ART in settings where WHO ART guidelines are applied.

114 dye technique can be used for SLN biopsy in settings where nuclear medicine facilities are not avail

115 tudy may have important implications both in settings where the immunogenic function of DCs is desira

116 we describe a method for genotype calling in settings where sequence data are available for unrelated

117 us, but its interpretation is challenging in settings where inflammation is common because RBP concen

118 listeners report difficulty communicating in settings where there are competing sound sources, but th

119 nature of selection and its consequences in settings where focal traits vary over the lifetime throu

120 In contrast, in settings where CTLA-4(+) cells were present as "regulato

121 self-reported mammographic screening data in settings where women are screened more than once.

122 need antimalarial treatment is difficult in settings where confirmatory laboratory testing is not av

123 haemodialysis for many patients with ESKD in settings where infrastructure permits.

124 on favorable to immunotherapy, especially in settings where donor lymphocytes are unavailable such as

125 e diagnosis of trichomoniasis, especially in settings where microscopy is impractical.

126 failure of model convergence, especially in settings where the prevalence of M. tuberculosis infecti

127 es of these types of immunity, especially in settings where there is emerging evidence of antagonism

128 ting is recommended for all adults except in settings where there is evidence that the prevalence of

129 y decrease the therapeutic efficacy of FL in settings where increased numbers of DCs might provide cl

130 r in response to viral antigen was higher in settings where more severe disease occurred.

131 However, in settings where both CD4 cell counts and viral load testi

132 r tolerance may be particularly important in settings where RTEs comprise a large fraction of the per

133 and measures over time is often important in settings where study subjects have incomplete or differe

134 they became profoundly anti-inflammatory in settings where they would normally be classically activa

135 icting paired macromolecular interactions in settings where high-throughput affinity data are availab

136 hould examine elective induction of labor in settings where most obstetric care is provided.

137 fected persons require revision, at least in settings where prophylaxis with this agent is common.

138 e of antimalarial drugs to infants living in settings where malaria is endemic, at the time of routin

139 nostimulatory monoclonal antibodies (mAb) in settings where the receptors targeted by the mAbs are ex

140 dy found that the disparity was magnified in settings where resources were greatest.

141 standard regimens and clinical monitoring in settings where laboratory infrastructure was not availab

142 uld have the greatest impact on mortality in settings where resources for HIV testing and linkage are

143 s of Mycobacterium tuberculosis may occur in settings where the infection pressure is high.

144 y-two percent of all pregnancies occurred in settings where the quintuple dhfr/dhps haplotype had bec

145 ipeptide, and that the role of NIK occurs in settings where both the Nod2 and TLR4 pathways are activ

146 nately, the BUM approach is reliable only in settings where the assumed model accurately represents t

147 endations while awaiting trial results or in settings where trials may be infeasible.

148 These data support use of oxytocin in settings where it is available.

149 at donor autonomy should not be paramount in settings where the recipient benefit is uncertain.

150 icians is therefore evident, particularly in settings where childhood tuberculosis is common, and bac

151 the technique for patients, particularly in settings where clinical presentations are diverse and ch

152 children with suspected PTB, particularly in settings where IS and culture are not feasible.

153 ial mortality and morbidity, particularly in settings where people lack improved sanitation and safe

154 understanding of RSV trends, particularly in settings where testing and reporting are most active.

155 ic technologies and that can be performed in settings where laboratory infrastructure is minimal.

156 ical inoculation rates but lack precision in settings where seroprevalence is still high.

157 ould be under negative selection pressure in settings where choline intake is low: choline dehydrogen

158 g are valid measures of operative quality in settings where follow-up is poor.

159 to establish whether this effect remains in settings where infection-prevention bundles of care are

160 lume method have the best reproducibility in settings where assessment is not performed by the same p

161 Research in settings where hypothermia is common is needed to determ

162 w therapeutic avenues to boost resolution in settings where defective resolution promotes disease pro

163 ion of models for predicting disease risk in settings where A. albopictus is present.

164 vides further evidence for the use of RMS in settings where CS are unavailable or unaffordable, or re

165 ggest that the deployment of DGT samplers in settings where nanoparticles are relevant (e.g., sedimen

166 fective far sooner, and even cost-saving, in settings where long-term health-care costs of late-diagn

167 n important new way to increase screening in settings where cytology is not readily performed.

168 is best implemented as an initial service in settings where services are scarce, for example in rural

169 t elevation myocardial infarction (STEMI) in settings where health-care resources are scarce.

170 needed to make MSAT an effective strategy in settings where malaria elimination programs are in the p

171 h cohort, research and evaluation studies in settings where persons who inject drugs receive services

172 he safety of routine iron supplementation in settings where infectious diseases, particularly malaria

173 t women who are virologically suppressed, in settings where therapeutic drug monitoring and/or close

174 This work provides evidence that in settings where there is a dominant source of biomass com

175 irus type 1 (HIV-1) vertical transmission in settings where it is routinely practiced.

176 vention and call for effectiveness trials in settings where it could be sustainably delivered.

177 radiolabeled probes and allowing its use in settings where malaria is endemic.

178 LPAs have a continued role for use in settings where rapid identification of INH resistance an

179 CD), in the Mediterranean area, when used in settings where it was designed to be administered, espec

180 uccess rate, TAP blocks remain under used in settings where patients could most benefit from their us

181 d nested case-control designs can be used in settings where the research aim is to evaluate the predi

182 er time, and could be particularly useful in settings where influenza activity is delayed or prolonge

183 argeted approaches may have more validity in settings where human settlement is more nuclear.

184 t similar adducts would be formed in vivo in settings where cyclooxygenase-2 expression is increased.

185 Exceptions include settings where fungal pathogens other than Cryptococcus

186 hest preterm birth rates occur in low-income settings where the causes of prematurity might differ an

187 blic health concern especially in low-income settings where these sources are used untreated.

188 d impact studies, particularly in low-income settings, where pneumococcal disease burden remains high

189 regation is a major problem in an industrial setting where antibody therapeutics often require high l

190 in models of outdoor, indoor, and industrial settings where particles are formed, and where accurate

191 l numbers is a serious concern in industrial settings where qPCR estimates form the basis for quality

192 anisms that are relevant to the inflammatory settings where these proinflammatory cytokines play a cr

193 are likely to be faced in all international settings where there is increased reliance on a support

194 a versatile role - in several international settings where candidate biomedical HIV prevention inter

195 the point of injection to the intracellular setting where functional gene silencing occurs.

196 ly test single animals in limited laboratory settings where the important effects of social interacti

197 w period in blood donors in resource limited settings where nucleic acid testing is not practical or

198 mation systems and two from resource-limited settings where clinicians maintain locally developed dat

199 of HIV-1 drug resistance in resource-limited settings where combination antiretroviral treatment has

200 periodontitis screening in resource-limited settings where gold standard clinical examination may no

201 patient care, especially in resource-limited settings where laboratory infrastructure is poor and the

202 In resource-limited settings where no safe alternative to breastfeeding exis

203 INTERPRETATION: In resource-limited settings where no suitable alternative to breastfeeding

204 and third-line regimens in resource-limited settings where subtype C predominates.

205 s have impeded their use in resource-limited settings where such diseases are endemic.

206 imen may have importance in resource-limited settings where the monetary cost of continuous ART is pr

207 t is an emerging problem in resource-limited settings where, in efforts to stem mother-to-child-trans

208 lly positive, especially in resource-limited settings, where the majority of vulnerable populations r

209 thology applications and in resource-limited settings, where whole-slide scanning microscopy systems

210 ls, primary care clinics and EDs are logical settings where screening that leads to intervention can

211 he context of real-world clinical management settings, where varying durations of and gaps in treatme

212 through Phanerozoic shales to modern marine settings, where marine dissolved and sedimentary delta(6

213 This is especially true in microbial settings where differential expression and regulation of

214 alpha-emitters are highly efficacious in MRD settings, where isolated cells and small tumor clusters

215 both are expressed specifically in multiple settings where N signaling takes place.

216 Furthermore, in a more natural setting where both sources of information were available

217 have already been adopted in the neoadjuvant setting where treatment toxicity will not be compounded

218 anic solvents are ubiquitous in occupational settings where they may contribute to risks for carcinog

219 chanisms for retaining iron in surface ocean settings where it limits productivity.

220 xity is illustrated by the identification of settings where autophagy acts potently to either promote

221 may be estimated without bias in a number of settings where researchers might otherwise assume that b

222 Our results considerably extend the range of settings where high-dimensional regression adjustments a

223 perturbing gene deactivation in a variety of settings where the network might operate.

224 al evaluation in a broad number of oncologic settings where mTOR signaling has a pathogenic role.

225 ormed efficiently in large surveys and other settings where approximate VA should be measured.

226 ther study of Id/KLH is recommended in other settings where efficacy may be further enhanced as in fi

227 tand neural and behavior mechanisms in other settings where emergent group-level activity exhibits mi

228 eful in high-prevalence areas or in outbreak settings where rapid carbapenemase detection is critical

229 ecule may be useful in multiple pathological settings where LRP1 blockade has been shown to be effect

230 findings suggest that in true physiological settings where multiple growth factors are present, acti

231 challenges are even greater in resource-poor settings where costs and logistical problems with delive

232 ocin--most are not feasible in resource-poor settings where many births occur at home.

233 idly to disease, especially in resource-poor settings where mortality is greater than 50% by 2 years

234 are particularly important in resource-poor settings where we may have underestimated cases.

235 m is particularly suitable for resource-poor settings, where centralized laboratory facilities, funds

236 In resource-poor settings, where limited drug options are the rule, when

237 ore are not optimal for use in resource-poor settings, where most cervical HPV disease occurs.

238 Physicians and nurses from practice settings where advance care planning typically takes pla

239 Otest kits may be reused in a low prevalence setting where cost issues remain paramount.

240 ormance of standard MI and MID in regression settings where data were missing on both the outcome and

241 zation at primary care clinics and in remote settings, where resources are limited.

242 Its use should be reserved for research settings where treatment regimens and imaging conditions

243 elated diseases and in a variety of research settings where sphingomyelin quantification is required.

244 t directly applicable to laboratory research settings, where adaptable, inexpensive and predictable p

245 ation in genomics studies and other research settings, where covariances differ among classes.

246 it global health through use in low-resource settings where central hematology laboratories are not a

247 s global relevance, we focus on low-resource settings where rates of poverty are highest and access t

248 made increasingly available in low-resource settings where they are most needed.

249 ion ASSURED criteria for use in low resource settings, where laboratory-based analytical procedures a

250 the efficacy of TAP blocks in low-resourced settings where patients do not have dependable access to

251 mial infection occurs in resource-restricted settings where barriers to transmission are lower.

252 dress whether this applies to urban riparian settings, where discharging groundwater may potentially

253 less well equipped laboratories and in rural settings where resources are limited.

254 Consider the simple setting where a diallelic autosomal candidate gene and a

255 ciency of biologically plausible socialtaxis settings, where agents share little or no information an

256 thdrawn have been less successful in the SOT setting where continued immunosuppression therapy is nec

257 articipant has no power, than in a strategic setting, where the other participant can punish unfair b

258 Improving care in such settings, where most health care practitioners do not ha

259 It is in such settings, where scientific research is often considered

260 io is different from the standard supervised setting, where each classifier's accuracy can be assesse

261 We study regression M-estimates in the setting where p, the number of covariates, and n, the nu

262 In the setting where the parents donate to the F1 offspring, re

263 closure and perception of risk depend on the setting where partners are encountered.

264 que of canonical correlation analysis to the setting where original individual-level records are not

265 patients, and should be available in all the settings where they access care.

266 However, the settings where this strategy would be cost effective in

267 Information is summarized within the settings where children live, learn, and play (early car

268 In a therapeutic setting where CpG was administered after allergen sensit

269 nterquartile range, 2.8-16.8 months) in this setting where viral load monitoring was available.

270 weight HA can cross-link CD44 only in those settings where it predominates over fragmentary LMW-HA,

271 case-control studies, which is applicable to settings where the exposure variable is polytomous and w

272 sibility was explored in a military training setting, where rates of febrile respiratory illness (FRI

273 ess have been described in the primary tumor setting, where the balance of protumor and antitumor res

274 ontrast with the intuitive and commonly used setting where capacity of a line is a fixed factor of it

275 ression system, and may be useful in vaccine settings where short-term cytoplasmic expression of prot

276 to test potential therapeutics in an in vivo setting where GNAQ(Q209L) mutations contribute to both t

277 n born in Hong Kong, a developed non-Western setting, where many children have migrant parents from m